New HIV combo shot shows promise in early trial

NCT ID NCT05996471

Ongoing Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tests a new drug, VH3810109, given with another HIV medicine (cabotegravir) in adults whose HIV is already well-controlled. The goal is to see if this combination can keep the virus suppressed as well as standard treatments. About 185 participants will receive either the new combo or standard care, and researchers will monitor viral levels and side effects over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Birmingham, Alabama, 35222, United States
GSK Investigational Site

Bakersfield, California, 93309, United States
GSK Investigational Site

Los Angeles, California, 90027, United States
GSK Investigational Site

Los Angeles, California, 90069, United States
GSK Investigational Site

Palm Springs, California, 92262, United States
GSK Investigational Site

Sacramento, California, 95825, United States
GSK Investigational Site

San Francisco, California, 94110, United States
GSK Investigational Site

New Haven, Connecticut, 06510, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20007, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20037, United States
GSK Investigational Site

Fort Lauderdale, Florida, 33308, United States
GSK Investigational Site

Ft. Pierce, Florida, 34982, United States
GSK Investigational Site

Miami, Florida, 33133, United States
GSK Investigational Site

Orlando, Florida, 32803, United States
GSK Investigational Site

Pensacola, Florida, 32503, United States
GSK Investigational Site

Sarasota, Florida, 34237, United States
GSK Investigational Site

Vero Beach, Florida, 32960, United States
GSK Investigational Site

West Palm Beach, Florida, 33409, United States
GSK Investigational Site

Decatur, Georgia, 30033, United States
GSK Investigational Site

Chicago, Illinois, 60611, United States
GSK Investigational Site

Boston, Massachusetts, 02115, United States
GSK Investigational Site

Springfield, Massachusetts, 01105, United States
GSK Investigational Site

Southfield, Michigan, 48075, United States
GSK Investigational Site

Columbia, Missouri, 65212, United States
GSK Investigational Site

Newark, New Jersey, 07102, United States
GSK Investigational Site

Albuquerque, New Mexico, 87109, United States
GSK Investigational Site

Santa Fe, New Mexico, 87505, United States
GSK Investigational Site

Manhasset, New York, 11030, United States
GSK Investigational Site

New York, New York, 10029, United States
GSK Investigational Site

New York, New York, 10032, United States
GSK Investigational Site

New York, New York, 10461, United States
GSK Investigational Site

The Bronx, New York, 10467, United States
GSK Investigational Site

Greensboro, North Carolina, 27401-1209, United States
GSK Investigational Site

Cincinnati, Ohio, 45267, United States
GSK Investigational Site

Portland, Oregon, 97239, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Nashville, Tennessee, 37208, United States
GSK Investigational Site

Austin, Texas, 78705, United States
GSK Investigational Site

Dallas, Texas, 75246, United States
GSK Investigational Site

El Paso, Texas, 79902, United States
GSK Investigational Site

Houston, Texas, 77030, United States
GSK Investigational Site

Houston, Texas, 77098, United States
GSK Investigational Site

Milwaukee, Wisconsin, 53226, United States
GSK Investigational Site

San Juan, 00909, Puerto Rico
GSK Investigational Site

San Juan, 909, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.